<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717155</url>
  </required_header>
  <id_info>
    <org_study_id>MS201944_0170</org_study_id>
    <secondary_id>2018-001529-24</secondary_id>
    <nct_id>NCT03717155</nct_id>
  </id_info>
  <brief_title>Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With Squamous Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase IIa, Single-arm, Multicenter Study to Investigate the Clinical Activity and Safety of Avelumab in Combination With Cetuximab Plus Gemcitabine and Cisplatin in Participants With Advanced Squamous Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to investigate the clinical activity and safety of avelumab
      in combination with cetuximab plus gemcitabine and cisplatin in participants with
      treatment-na√Øve advanced squamous NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">February 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigator</measure>
    <time_frame>From the first dose of study intervention until planned final assessment at Month 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-emergent Adverse Events (TEAEs), Treatment-related AEs, Treatment-related Grade &gt;= 3 AEs, and Immune-related AEs According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)</measure>
    <time_frame>From the first dose of study intervention until planned final assessment at Month 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) Time According to RECIST v 1.1 Assessed by Investigator</measure>
    <time_frame>From the first dose of study intervention until planned final assessment at Month 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as Assessed by Investigator</measure>
    <time_frame>From the first dose of study intervention until planned final assessment at Month 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Serum Concentration of Avelumab and Cetuximab</measure>
    <time_frame>Pre-dose up to Week 49/progressive disease (PD), end of treatment (within 7 days of treatment discontinuation), safety follow up (30 days +/- 5 days after last treatment), assessed approximately up to a maximum of Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum Concentration of Avelumab and Cetuximab</measure>
    <time_frame>Pre-dose up to Week 49/progressive disease (PD), end of treatment (within 7 days of treatment discontinuation), safety follow up (30 days +/- 5 days after last treatment), assessed approximately up to a maximum of Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Antidrug Antibody (ADA) Assay of Avelumab and Cetuximab in Combination Therapy</measure>
    <time_frame>From the first dose of study intervention until planned final assessment at Month 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the first dose of study intervention until planned final assessment at Month 17</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Avelumab + Cetuximab + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Participants will receive avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, it will be given every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.</description>
    <arm_group_label>Avelumab + Cetuximab + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Participants will receive cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m^2) body surface area on Day 1 and 500 mg/m^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, it will be given at a dose of 500 mg/m^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.</description>
    <arm_group_label>Avelumab + Cetuximab + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Participants will receive gemcitabine intravenous infusions at a dose of 1250 mg/m^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles.</description>
    <arm_group_label>Avelumab + Cetuximab + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Participants will receive cisplatin intravenous infusions at a dose of 75 mg/m^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles.</description>
    <arm_group_label>Avelumab + Cetuximab + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed Stage IV metastatic or recurrent (Stage IV) NSCLC of squamous
             histology

          -  Availability of formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue
             or a minimum of 15 (preferably 25) unstained tumor slides (cut within 1 week) suitable
             for Programmed death ligand 1 (PD-L1) expression and epidermal growth factor receptor
             (EGFR) expression/amplification assessments

          -  At least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST)
             v1.1 criteria

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study
             entry

          -  Adequate hematological, hepatic and renal function

          -  Estimated life expectancy of at least 3 months

          -  Can give signed informed consent

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants whose tumor disease harbors an activating EGFR mutation or ALK
             rearrangement. Participants with tumors of unknown EGFR or ALK status will require
             testing only in never smokers

          -  All participants with brain metastases with protocol defined exceptions

          -  Previous malignant disease (other than NSCLC) within the last 5 years (except
             adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder,
             cervix, colon/rectum, breast, or prostate) unless a complete remission without further
             recurrence was achieved at least 2 years prior to study entry and the participant was
             deemed to have been cured with no additional therapy required or anticipated to be
             required

          -  Active infection requiring systemic therapy

          -  Known history of human immunodeficiency virus or known acquired immunodeficiency
             syndrome

          -  Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive
             HBV surface antigen or HCV ribonucleic acid (RNA) if anti-HCV antibody screening test
             positive)

          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent

          -  Interstitial parenchymal lung disease

          -  Pregnancy or lactation

          -  Known alcohol or drug abuse as determined by the Investigator

          -  History of uncontrolled intercurrent illness

          -  Clinically significant (that is active) cardiovascular disease

          -  Known history of inflammatory colitis, inflammatory bowel disease, pneumonitis,
             pulmonary fibrosis

          -  Any psychiatric condition that would prohibit the understanding or rendering of
             informed consent or that would limit compliance with study requirements

          -  Prior/Concomitant Therapy as described in protocol

          -  Use of any investigational drug within 28 days before the start of study treatment

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Pulmonologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem - Tudogyogyaszati Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatokorhaz</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tudogyogyintezet Torokbalint - Onkopulmonologiai es Jarobeteg centrum</name>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Korhaz</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center &quot;Bezanijska kosa&quot; - Department of Oncology</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac (no dept.)</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Pulmonary Diseases of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coru√±a - Servicio de Oncologia</name>
      <address>
        <city>A Coru√±a</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron - Dept of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Mara√±on - Servicio de Oncologia Medica</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>M√°laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena - Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa - Dept of Oncology</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avelumab</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

